Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YL202 in Locally Advanced or Metastatic Breast Cancer
NCT06439771Phase 2Recruiting
- Sponsor
- MediLink Therapeutics
- Start
- Apr 2024
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of YL202 in breast cancer (3 arms), sponsored by MediLink Therapeutics. Primary endpoints: Objective Response Rate at 36 months and Recommended Dose for Pivotal Clinical Study at 36 months. Started Apr 2024; status: recruiting.
02
Drugs
YL202
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06439771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06439771.